These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34924163)

  • 1. Interpretation of clinical trials on the cardiovascular effects of hypoglycemic drugs in people with type 2 diabetes.
    Romero A; Llauradó G; González-Clemente JM
    Endocrinol Diabetes Nutr (Engl Ed); 2021 Dec; 68(10):741-750. PubMed ID: 34924163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interpretation of clinical trials on the cardiovascular effects of hypoglycemic drugs in people with type2 diabetes.
    Romero A; Llauradó G; González-Clemente JM
    Endocrinol Diabetes Nutr (Engl Ed); 2021 May; ():. PubMed ID: 33965366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New glucose-lowering drugs for reducing cardiovascular risk in patients with type2 diabetes mellitus].
    Gorgojo-Martínez JJ
    Hipertens Riesgo Vasc; 2019; 36(3):145-161. PubMed ID: 31079957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Type 2 diabetes mellitus: new treatments].
    Ascaso JF
    Med Clin (Barc); 2014 Aug; 143(3):117-23. PubMed ID: 23937815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of antihyperglycaemic therapy with cardiovascular benefit in patients with type 2 diabetes who require hospitalisation: A cross-sectional study.
    Ena J; Carretero-Gómez J; Zapatero-Gaviria A; Carrasco-Sánchez FJ; Del Romero-Sánchez M; González-Becerra C; Blazquez-Encinar JC; Iguzquiza-Pellejero MJ; de Escalante Yangüela B; Gómez-Huelgas R;
    Rev Clin Esp (Barc); 2021 Nov; 221(9):517-528. PubMed ID: 34752263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.
    Shin JI
    Curr Diab Rep; 2019 Jul; 19(8):54. PubMed ID: 31286271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus].
    Mauricio D
    Med Clin (Barc); 2013 Sep; 141 Suppl 2():31-5. PubMed ID: 24444522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of newer antidiabetic drugs on cardiovascular prevention and heart failure.
    Rojas-Velázquez JM; Giralt-Herrera A; Leiva-Enríquez J; Leiva-Enríquez J
    Clin Investig Arterioscler; 2021; 33(6):314-322. PubMed ID: 33820673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
    Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
    Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
    Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positioning of sodium-glucose cotransporter-2 inhibitors in national and international guidelines.
    Morillas C
    Med Clin (Barc); 2016 Nov; 147 Suppl 1():49-53. PubMed ID: 28760226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes.
    Garg V; Verma S; Connelly K
    Prog Cardiovasc Dis; 2019; 62(4):349-357. PubMed ID: 31381891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical profile of patients with type 2 diabetes mellitus treated with sodium- glucose cotransporter-2 inhibitors and experience in real-world clinical practice in Spain.
    Cuatrecasas G; Goñi-Goicoechea F
    Med Clin (Barc); 2016 Nov; 147 Suppl 1():30-34. PubMed ID: 28760223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
    Ghosh-Swaby OR; Goodman SG; Leiter LA; Cheng A; Connelly KA; Fitchett D; Jüni P; Farkouh ME; Udell JA
    Lancet Diabetes Endocrinol; 2020 May; 8(5):418-435. PubMed ID: 32333878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D; Javor E; Lucijanić T; Skelin M
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Cardiovascular Safety of SGLT2 Inhibitors.
    Fernandez CJ; Nevins AG; Nawaz S; Nazir T; Hanna FWF
    Curr Drug Saf; 2021; 16(2):178-196. PubMed ID: 33006538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
    Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
    Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
    Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.